This newslink doesn't exist or it was removed.
Go to Homempage.
CNBC USA Politics January 20, 2023
In this articleMartin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, center, pauses while speak to members of the media with his attorney Benjamin Brafman, right, outside federal court in the Brooklyn borough of New York, U.S., on Friday, Aug. 4,... + más
FTC: Shkreli may have violated lifetime pharma ban, should be held in contempt | Ars Technica
FTC files motion seeking for 'Pharma Bro' Martin Shkreli to be held in contempt | Fox Business
Ars Technica USA Science February 14, 2023
Navigate Filter by topic Settings Front page layout Site theme - Feb 13, 2023 11:20 pm UTC / Martin Shkreli arrives at Brooklyn Federal Court on the first day of his securities fraud trial in 2017. Share this story In an effort to avoid being held in contempt of court, former... + más
FTC asks judge to hold 'pharma bro' Martin Shkreli in contempt of court for forming new drug firm | CNBC
Ars Technica USA Science January 20, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 20, 2023 10:21 pm UTC / Martin Shkreli, former CEO of Turing, smirked his way through a congressional hearing. Share this story Infamous ex-pharmaceutical executive Martin Shkreli is yet again in trouble with... + más
New York Post USA Tech August 31, 2023
It’s Pharma Bro vs the World’s Richest Man. Martin Shkreli, who spent four and a half years in federal prison for securities fraud and gained infamy for alleged price gauging of a life-saving drug, says he’s been lobbying Elon Musk through mutual friends to give him... + más
Shkreli tells judge his drug discovery software is not for discovering drugs | Ars Technica
Ars Technica USA Science May 12, 2023
Navigate Filter by topic Settings Front page layout Site theme - May 11, 2023 8:10 pm UTC / Martin Shkreli. The pharmaceutical company behind Martin Shkreli's infamous 4,000 percent price hike—now known as Vyera Pharmaceuticals—filed for bankruptcy this week and plans... + más
About iurex | Privacy Policy | Disclaimer |